 Cindy O'Bryant
Concepts (316)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 22 | 2025 | 2231 | 1.780 |
Why?
| | Neoplasms | 32 | 2025 | 2946 | 1.540 |
Why?
| | Antiemetics | 2 | 2024 | 51 | 0.800 |
Why?
| | Piperidines | 3 | 2021 | 224 | 0.760 |
Why?
| | Pyridines | 5 | 2015 | 610 | 0.750 |
Why?
| | Pharmacists | 5 | 2025 | 259 | 0.680 |
Why?
| | Indazoles | 1 | 2021 | 86 | 0.660 |
Why?
| | Anilides | 2 | 2013 | 84 | 0.650 |
Why?
| | Liver | 3 | 2021 | 1916 | 0.630 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 48 | 0.590 |
Why?
| | Immunoconjugates | 2 | 2023 | 138 | 0.580 |
Why?
| | Morpholines | 1 | 2020 | 130 | 0.580 |
Why?
| | Cisplatin | 5 | 2024 | 347 | 0.580 |
Why?
| | Drug Hypersensitivity | 1 | 2020 | 93 | 0.550 |
Why?
| | Drug Interactions | 6 | 2024 | 405 | 0.520 |
Why?
| | Protein Kinase Inhibitors | 5 | 2024 | 984 | 0.490 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2019 | 219 | 0.470 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2015 | 231 | 0.420 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 2001 | 0.390 |
Why?
| | Dose-Response Relationship, Drug | 13 | 2021 | 2030 | 0.380 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2026 | 1195 | 0.380 |
Why?
| | Medical Oncology | 3 | 2025 | 344 | 0.370 |
Why?
| | Depsipeptides | 1 | 2012 | 15 | 0.370 |
Why?
| | Quinazolines | 2 | 2011 | 266 | 0.370 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2012 | 45 | 0.360 |
Why?
| | Area Under Curve | 8 | 2021 | 334 | 0.340 |
Why?
| | Pyrazoles | 2 | 2013 | 518 | 0.340 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2026 | 1005 | 0.330 |
Why?
| | Sulindac | 2 | 2008 | 16 | 0.330 |
Why?
| | Sirolimus | 1 | 2012 | 283 | 0.320 |
Why?
| | Neuroendocrine Tumors | 1 | 2012 | 123 | 0.320 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 445 | 0.320 |
Why?
| | Nitriles | 2 | 2008 | 211 | 0.310 |
Why?
| | Skin Neoplasms | 2 | 2017 | 865 | 0.310 |
Why?
| | Aged | 31 | 2026 | 26514 | 0.300 |
Why?
| | Middle Aged | 34 | 2026 | 36821 | 0.290 |
Why?
| | Lung Neoplasms | 3 | 2026 | 2679 | 0.280 |
Why?
| | Tosyl Compounds | 1 | 2008 | 17 | 0.280 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 81 | 0.270 |
Why?
| | Drug Dosage Calculations | 1 | 2008 | 27 | 0.270 |
Why?
| | Bone Density Conservation Agents | 1 | 2008 | 82 | 0.260 |
Why?
| | Androgen Antagonists | 1 | 2008 | 91 | 0.260 |
Why?
| | Liver Failure, Acute | 1 | 2008 | 70 | 0.260 |
Why?
| | Food | 1 | 2008 | 150 | 0.250 |
Why?
| | Pain | 3 | 2011 | 794 | 0.240 |
Why?
| | Fasting | 1 | 2008 | 280 | 0.240 |
Why?
| | Breast Neoplasms | 3 | 2023 | 2420 | 0.240 |
Why?
| | Humans | 52 | 2026 | 147293 | 0.230 |
Why?
| | Aged, 80 and over | 10 | 2024 | 8430 | 0.230 |
Why?
| | Osteoporosis | 1 | 2008 | 239 | 0.230 |
Why?
| | Liver Diseases | 2 | 2019 | 307 | 0.220 |
Why?
| | Acute Kidney Injury | 3 | 2018 | 880 | 0.220 |
Why?
| | Professional Role | 2 | 2017 | 171 | 0.220 |
Why?
| | Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 5 | 0.220 |
Why?
| | Administration, Oral | 5 | 2012 | 874 | 0.210 |
Why?
| | Deoxycytidine | 5 | 2011 | 220 | 0.210 |
Why?
| | Female | 36 | 2026 | 80076 | 0.210 |
Why?
| | Platinum | 1 | 2024 | 48 | 0.210 |
Why?
| | Maximum Tolerated Dose | 10 | 2020 | 217 | 0.210 |
Why?
| | Hedgehog Proteins | 2 | 2017 | 201 | 0.200 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1514 | 0.200 |
Why?
| | Male | 35 | 2026 | 73950 | 0.200 |
Why?
| | Nausea | 4 | 2020 | 112 | 0.200 |
Why?
| | Pancreatic Neoplasms | 1 | 2012 | 947 | 0.200 |
Why?
| | Midazolam | 1 | 2024 | 73 | 0.200 |
Why?
| | Adult | 28 | 2025 | 41405 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 4 | 2010 | 239 | 0.190 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2024 | 93 | 0.190 |
Why?
| | Vomiting | 3 | 2020 | 131 | 0.180 |
Why?
| | ErbB Receptors | 2 | 2017 | 638 | 0.170 |
Why?
| | Prostatic Neoplasms | 1 | 2008 | 986 | 0.160 |
Why?
| | Apoptosis | 3 | 2008 | 2454 | 0.160 |
Why?
| | Sulfonamides | 2 | 2019 | 596 | 0.160 |
Why?
| | Cohort Studies | 5 | 2020 | 6099 | 0.160 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2023 | 220 | 0.160 |
Why?
| | Lymphoma | 2 | 2016 | 253 | 0.160 |
Why?
| | Pyrimidines | 2 | 2024 | 532 | 0.160 |
Why?
| | Trastuzumab | 2 | 2023 | 119 | 0.160 |
Why?
| | Benzoxazoles | 1 | 2020 | 20 | 0.160 |
Why?
| | Fluorouracil | 4 | 2011 | 232 | 0.160 |
Why?
| | Drug Evaluation | 1 | 2020 | 79 | 0.150 |
Why?
| | Azepines | 1 | 2020 | 105 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1431 | 0.150 |
Why?
| | Patient Care Team | 1 | 2025 | 712 | 0.150 |
Why?
| | Hydroxamic Acids | 1 | 2019 | 95 | 0.150 |
Why?
| | Analgesics, Opioid | 1 | 2008 | 1167 | 0.140 |
Why?
| | TWEAK Receptor | 1 | 2017 | 6 | 0.130 |
Why?
| | Models, Biological | 1 | 2024 | 1772 | 0.130 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 35 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2014 | 552 | 0.130 |
Why?
| | Hematology | 1 | 2017 | 21 | 0.130 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 48 | 0.120 |
Why?
| | Pharmaceutical Services | 1 | 2017 | 76 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2020 | 566 | 0.120 |
Why?
| | Maytansine | 1 | 2016 | 18 | 0.120 |
Why?
| | Aminoglycosides | 1 | 2016 | 30 | 0.120 |
Why?
| | Specialty Boards | 1 | 2016 | 42 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 288 | 0.110 |
Why?
| | Pain Management | 2 | 2017 | 415 | 0.110 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2973 | 0.110 |
Why?
| | Drugs, Investigational | 1 | 2015 | 31 | 0.110 |
Why?
| | Carbazoles | 1 | 2015 | 53 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2016 | 111 | 0.110 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 122 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 440 | 0.110 |
Why?
| | American Heart Association | 1 | 2016 | 363 | 0.110 |
Why?
| | Biomarkers, Tumor | 4 | 2010 | 1339 | 0.110 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2014 | 13 | 0.100 |
Why?
| | Insurance Claim Review | 1 | 2014 | 86 | 0.100 |
Why?
| | Drug Administration Schedule | 5 | 2019 | 789 | 0.100 |
Why?
| | Carboplatin | 3 | 2009 | 168 | 0.100 |
Why?
| | Specialization | 1 | 2014 | 137 | 0.100 |
Why?
| | Retrospective Studies | 5 | 2026 | 17560 | 0.090 |
Why?
| | Chronic Pain | 1 | 2017 | 301 | 0.090 |
Why?
| | Gonanes | 1 | 2012 | 23 | 0.090 |
Why?
| | Everolimus | 1 | 2012 | 112 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 347 | 0.090 |
Why?
| | Signal Transduction | 2 | 2017 | 5272 | 0.090 |
Why?
| | Erlotinib Hydrochloride | 1 | 2011 | 72 | 0.090 |
Why?
| | Biomarkers | 3 | 2018 | 4351 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2011 | 105 | 0.080 |
Why?
| | Phytotherapy | 1 | 2011 | 74 | 0.080 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1072 | 0.080 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 822 | 0.080 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 303 | 0.080 |
Why?
| | Glucuronidase | 2 | 2008 | 27 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 767 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 48 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2011 | 512 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 2014 | 522 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1082 | 0.080 |
Why?
| | Oligosaccharides | 2 | 2008 | 61 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 87 | 0.070 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 31 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2017 | 2529 | 0.070 |
Why?
| | Kidney | 1 | 2017 | 1511 | 0.070 |
Why?
| | Cannabinoids | 1 | 2011 | 184 | 0.070 |
Why?
| | Primary Health Care | 2 | 2017 | 1759 | 0.070 |
Why?
| | Drug Monitoring | 1 | 2013 | 402 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 456 | 0.070 |
Why?
| | Treatment Outcome | 7 | 2015 | 11947 | 0.070 |
Why?
| | Education, Pharmacy, Continuing | 1 | 2008 | 1 | 0.070 |
Why?
| | Capecitabine | 4 | 2011 | 56 | 0.070 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 700 | 0.070 |
Why?
| | Clinical Competence | 1 | 2017 | 1260 | 0.070 |
Why?
| | Equipment and Supplies | 1 | 2008 | 37 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 77 | 0.070 |
Why?
| | Boronic Acids | 1 | 2008 | 37 | 0.070 |
Why?
| | Taxoids | 2 | 2008 | 116 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1598 | 0.070 |
Why?
| | Marijuana Smoking | 1 | 2011 | 249 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2008 | 74 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2008 | 46 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 287 | 0.070 |
Why?
| | Farnesyltranstransferase | 1 | 2007 | 21 | 0.070 |
Why?
| | Etoposide | 1 | 2008 | 169 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2008 | 83 | 0.070 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 59 | 0.070 |
Why?
| | Reference Standards | 1 | 2008 | 177 | 0.070 |
Why?
| | Drug Prescriptions | 1 | 2010 | 293 | 0.070 |
Why?
| | Receptors, Vitronectin | 1 | 2007 | 5 | 0.070 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 127 | 0.070 |
Why?
| | Integrin alphaVbeta3 | 1 | 2007 | 20 | 0.070 |
Why?
| | Snake Venoms | 1 | 2007 | 20 | 0.060 |
Why?
| | Pyrazines | 1 | 2008 | 94 | 0.060 |
Why?
| | Absorptiometry, Photon | 1 | 2008 | 277 | 0.060 |
Why?
| | Oxycodone | 1 | 2008 | 52 | 0.060 |
Why?
| | Benzamides | 1 | 2008 | 227 | 0.060 |
Why?
| | Triazoles | 1 | 2008 | 191 | 0.060 |
Why?
| | Fatigue | 4 | 2012 | 367 | 0.060 |
Why?
| | Delayed-Action Preparations | 1 | 2008 | 191 | 0.060 |
Why?
| | Integrins | 1 | 2007 | 90 | 0.060 |
Why?
| | Pharmacogenetics | 1 | 2008 | 176 | 0.060 |
Why?
| | Anxiety Disorders | 1 | 2010 | 376 | 0.060 |
Why?
| | Morphine | 1 | 2008 | 169 | 0.060 |
Why?
| | Alkyl and Aryl Transferases | 1 | 2006 | 31 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2007 | 133 | 0.060 |
Why?
| | Fentanyl | 1 | 2008 | 128 | 0.060 |
Why?
| | Thiophenes | 1 | 2007 | 117 | 0.060 |
Why?
| | Animals | 6 | 2020 | 38410 | 0.060 |
Why?
| | Indoles | 2 | 2008 | 510 | 0.060 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 115 | 0.060 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 3565 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 593 | 0.060 |
Why?
| | Young Adult | 3 | 2020 | 14437 | 0.060 |
Why?
| | Methadone | 1 | 2008 | 131 | 0.060 |
Why?
| | Societies, Pharmaceutical | 2 | 2017 | 14 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 516 | 0.060 |
Why?
| | Nigeria | 1 | 2025 | 24 | 0.060 |
Why?
| | Protein Binding | 1 | 2011 | 2249 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1280 | 0.060 |
Why?
| | Risk Factors | 1 | 2020 | 11017 | 0.060 |
Why?
| | Granisetron | 1 | 2024 | 6 | 0.050 |
Why?
| | Quinuclidines | 1 | 2024 | 11 | 0.050 |
Why?
| | Ondansetron | 1 | 2024 | 20 | 0.050 |
Why?
| | Palliative Care | 2 | 2011 | 1032 | 0.050 |
Why?
| | Isoquinolines | 1 | 2024 | 44 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 575 | 0.050 |
Why?
| | Occupational Exposure | 1 | 2008 | 357 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 939 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2019 | 430 | 0.050 |
Why?
| | Cannabis | 1 | 2011 | 518 | 0.050 |
Why?
| | RNA, Catalytic | 1 | 2005 | 191 | 0.050 |
Why?
| | United States | 5 | 2017 | 16313 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 765 | 0.050 |
Why?
| | Quinolones | 1 | 2006 | 206 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6164 | 0.050 |
Why?
| | Prospective Studies | 3 | 2024 | 8164 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 889 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2015 | 2218 | 0.050 |
Why?
| | Camptothecin | 1 | 2023 | 138 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 221 | 0.050 |
Why?
| | Diarrhea | 2 | 2015 | 193 | 0.050 |
Why?
| | Heart Failure | 1 | 2016 | 2334 | 0.050 |
Why?
| | Adolescent | 2 | 2020 | 22825 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1776 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1492 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 61 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 138 | 0.040 |
Why?
| | Neutropenia | 2 | 2009 | 154 | 0.030 |
Why?
| | Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.030 |
Why?
| | Glutathione S-Transferase pi | 1 | 2017 | 10 | 0.030 |
Why?
| | Adenine | 1 | 2020 | 339 | 0.030 |
Why?
| | Organic Cation Transport Proteins | 1 | 2017 | 25 | 0.030 |
Why?
| | Partial Thromboplastin Time | 2 | 2008 | 53 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2018 | 335 | 0.030 |
Why?
| | Amidine-Lyases | 1 | 1997 | 1 | 0.030 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2007 | 25 | 0.030 |
Why?
| | Anemia | 2 | 2009 | 192 | 0.030 |
Why?
| | Mixed Function Oxygenases | 1 | 1997 | 43 | 0.030 |
Why?
| | Multienzyme Complexes | 1 | 1997 | 65 | 0.030 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 1997 | 55 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2008 | 6011 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 156 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2017 | 120 | 0.030 |
Why?
| | Paclitaxel | 2 | 2009 | 261 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 1003 | 0.030 |
Why?
| | Cardiotoxins | 1 | 2015 | 3 | 0.030 |
Why?
| | Drug Eruptions | 1 | 2015 | 28 | 0.030 |
Why?
| | Mucositis | 1 | 2015 | 20 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 383 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2017 | 124 | 0.030 |
Why?
| | Analgesics | 1 | 1997 | 231 | 0.030 |
Why?
| | Pharmacy Residencies | 1 | 2014 | 10 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1730 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5476 | 0.030 |
Why?
| | Drug Discovery | 1 | 2015 | 153 | 0.030 |
Why?
| | Students, Pharmacy | 1 | 2014 | 96 | 0.020 |
Why?
| | Stroke Volume | 1 | 2015 | 658 | 0.020 |
Why?
| | Electrocardiography | 1 | 2015 | 675 | 0.020 |
Why?
| | Dioxoles | 1 | 2011 | 9 | 0.020 |
Why?
| | Tetrahydroisoquinolines | 1 | 2011 | 8 | 0.020 |
Why?
| | Biological Availability | 1 | 2011 | 146 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2016 | 625 | 0.020 |
Why?
| | Mice | 3 | 2020 | 18491 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3660 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 383 | 0.020 |
Why?
| | Massage | 1 | 2010 | 42 | 0.020 |
Why?
| | Alopecia | 1 | 2009 | 37 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 74 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2014 | 697 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4383 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 42 | 0.020 |
Why?
| | Bortezomib | 1 | 2008 | 54 | 0.020 |
Why?
| | Maximum Allowable Concentration | 1 | 2008 | 16 | 0.020 |
Why?
| | Floxuridine | 1 | 2008 | 5 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2010 | 268 | 0.020 |
Why?
| | Protein Kinase C beta | 1 | 2008 | 21 | 0.020 |
Why?
| | Dibenzocycloheptenes | 1 | 2007 | 5 | 0.020 |
Why?
| | Platelet Factor 4 | 1 | 2008 | 36 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2008 | 94 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2007 | 120 | 0.020 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2007 | 17 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2007 | 58 | 0.020 |
Why?
| | Protein Prenylation | 1 | 2006 | 19 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2008 | 141 | 0.020 |
Why?
| | Carcinoid Tumor | 1 | 2006 | 21 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2006 | 30 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2008 | 251 | 0.020 |
Why?
| | Heparin | 1 | 2008 | 249 | 0.010 |
Why?
| | Thrombocytopenia | 1 | 2008 | 207 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 2007 | 182 | 0.010 |
Why?
| | Risk | 1 | 2008 | 927 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2006 | 108 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 222 | 0.010 |
Why?
| | Fibroblast Growth Factors | 1 | 2006 | 188 | 0.010 |
Why?
| | Inflammation | 1 | 1997 | 2920 | 0.010 |
Why?
| | Antibody Formation | 1 | 2006 | 288 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 109 | 0.010 |
Why?
| | Monocytes | 1 | 2008 | 539 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1281 | 0.010 |
Why?
| | Disease Progression | 1 | 2012 | 2890 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2006 | 233 | 0.010 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 267 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 178 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1721 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1481 | 0.010 |
Why?
| | Gastrointestinal Tract | 1 | 2004 | 204 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2007 | 886 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 4130 | 0.010 |
Why?
| | Melanoma | 1 | 2006 | 774 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2006 | 876 | 0.010 |
Why?
| | Carrageenan | 1 | 1997 | 8 | 0.010 |
Why?
| | Bradykinin | 1 | 1997 | 49 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3980 | 0.010 |
Why?
| | Substance P | 1 | 1997 | 38 | 0.010 |
Why?
| | Lyases | 1 | 1997 | 15 | 0.010 |
Why?
| | Edema | 1 | 1997 | 128 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1997 | 387 | 0.010 |
Why?
| | Serotonin | 1 | 1997 | 300 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1569 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 7173 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1997 | 2134 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1997 | 2542 | 0.010 |
Why?
| | Rats | 1 | 1997 | 5613 | 0.000 |
Why?
|
|
O'Bryant's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|